Showing results (701-710 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|February 4, 2021
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspectiveTobias Engel Ayer Botrel, Márcia Datz Abadi, Laura Chabrol Haas, et al.Journal of Medical Economics|October 4, 2019
Humanistic and economic burden among caregivers of patients with cancer in JapanShinya Ohno, Yirong Chen, Hiroyuki Sakamaki, et al.Journal of Medical Economics|October 4, 2019
Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UKGeorgia Hollier-Hann, Alistair Curry, Kateryna Onishchenko, et al.Journal of Medical Economics|October 8, 2019
Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United StatesFuraha Kariburyo, Lin Xie, Janvi Sah, et al.Journal of Medical Economics|August 27, 2020
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)Nimer S Alkhatib, Ali McBride, Marion Slack, et al.Journal of Medical Economics|August 27, 2020
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricingNimer S Alkhatib, Kenneth Ramos, Brian Erstad, et al.Journal of Medical Economics|August 27, 2020
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricingNimer S Alkhatib, Kenneth Ramos, Brian Erstad, et al.Journal of Medical Economics|January 5, 2026
A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer's diseaseRiccardo Ressa, Jack Ettinger, Emtiyaz Chowdhury, et al.Journal of Medical Economics|October 9, 2009
Examining and interpreting responsiveness of the Diabetes Medication Satisfaction measureMeryl Brod, Torsten Christensen, Jens Harald Kongsø, et al.Journal of Medical Economics|October 9, 2009
Cost effectiveness of palivizumab in children with congenital heart disease in GermanyMark Nuijten, Maximilian Lebmeier, Wolfgang WittenbergPageof 241